EE200200425A - Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid - Google Patents
Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadidInfo
- Publication number
- EE200200425A EE200200425A EEP200200425A EEP200200425A EE200200425A EE 200200425 A EE200200425 A EE 200200425A EE P200200425 A EEP200200425 A EE P200200425A EE P200200425 A EEP200200425 A EE P200200425A EE 200200425 A EE200200425 A EE 200200425A
- Authority
- EE
- Estonia
- Prior art keywords
- nicotinamide
- inhibitors
- useful
- selective pde4
- pde4 isozymes
- Prior art date
Links
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 title 1
- 108010044467 Isoenzymes Proteins 0.000 title 1
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229960003966 nicotinamide Drugs 0.000 title 1
- 235000005152 nicotinamide Nutrition 0.000 title 1
- 239000011570 nicotinamide Substances 0.000 title 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17928400P | 2000-01-31 | 2000-01-31 | |
PCT/IB2001/000124 WO2001057036A1 (fr) | 2000-01-31 | 2001-01-30 | Derives benzocondenses heterocycliques de nicotinamide utiles comme inhibiteurs selectifs d'isozymes pde4 |
Publications (1)
Publication Number | Publication Date |
---|---|
EE200200425A true EE200200425A (et) | 2003-10-15 |
Family
ID=22655931
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EEP200200425A EE200200425A (et) | 2000-01-31 | 2001-01-30 | Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid |
Country Status (40)
Country | Link |
---|---|
US (1) | US7354941B2 (fr) |
EP (1) | EP1252158B1 (fr) |
JP (1) | JP3917863B2 (fr) |
KR (1) | KR20020072299A (fr) |
CN (1) | CN1404481A (fr) |
AP (1) | AP2002002589A0 (fr) |
AR (1) | AR027337A1 (fr) |
AT (1) | ATE293624T1 (fr) |
AU (1) | AU2700201A (fr) |
BG (1) | BG106852A (fr) |
BR (1) | BR0107964A (fr) |
CA (1) | CA2398182C (fr) |
CO (1) | CO5261634A1 (fr) |
CZ (1) | CZ20022410A3 (fr) |
DE (1) | DE60110205T2 (fr) |
EA (1) | EA004885B1 (fr) |
EE (1) | EE200200425A (fr) |
ES (1) | ES2238415T3 (fr) |
GE (1) | GEP20043302B (fr) |
GT (1) | GT200100022A (fr) |
HN (1) | HN2001000019A (fr) |
HU (1) | HUP0204262A2 (fr) |
IL (1) | IL150641A0 (fr) |
IS (1) | IS6421A (fr) |
MA (1) | MA26870A1 (fr) |
MX (1) | MXPA02007419A (fr) |
NO (1) | NO20023613L (fr) |
NZ (1) | NZ519547A (fr) |
OA (1) | OA12169A (fr) |
PA (1) | PA8511201A1 (fr) |
PE (1) | PE20011058A1 (fr) |
PL (1) | PL357995A1 (fr) |
PT (1) | PT1252158E (fr) |
SK (1) | SK10142002A3 (fr) |
SV (1) | SV2002000299A (fr) |
TN (1) | TNSN01020A1 (fr) |
TR (1) | TR200201880T2 (fr) |
UY (1) | UY26569A1 (fr) |
WO (1) | WO2001057036A1 (fr) |
ZA (1) | ZA200206033B (fr) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69942009D1 (de) * | 1998-10-15 | 2010-03-25 | Imp Innovations Ltd | Verbindungen für die behandlung von gewichtsverlust |
DE60110057T2 (de) * | 2000-01-28 | 2005-09-08 | Alza Corp., Mountain View | Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung |
MXPA03002338A (es) * | 2000-09-18 | 2003-09-10 | Du Pont | Piridinilamidas y piridinilimidas para uso como fungicidas. |
WO2002060898A1 (fr) | 2001-01-31 | 2002-08-08 | Pfizer Products Inc. | Derives amide acide de thiazolyle, oxazolyle, pyrrolyle et imidazolyle utilises en tant qu'inhibiteurs des isozymes pde4 |
IL156460A0 (en) | 2001-01-31 | 2004-01-04 | Pfizer Prod Inc | Ether derivatives useful as inhibitors of pde4 isozymes |
EP1355884A1 (fr) * | 2001-01-31 | 2003-10-29 | Pfizer Products Inc. | Derives de biaryl nicotinamide utiles comme inhibiteurs d'isozymes de pde4 |
US7250518B2 (en) | 2001-01-31 | 2007-07-31 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
NZ532279A (en) * | 2001-09-19 | 2006-02-24 | Altana Pharma Ag | Combination of a PDE inhibitor and a leukotriene receptor antagonist |
DK1429807T3 (da) * | 2001-09-19 | 2007-06-18 | Altana Pharma Ag | Kombination af et NSAID og en PDE4-inhibitor |
IS7221A (is) * | 2001-11-15 | 2004-04-15 | Memory Pharmaceuticals Corporation | Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra |
DE60317466T2 (de) | 2002-02-11 | 2008-03-06 | Pfizer Inc. | Nicotinamidderivate, die als PDE4--Inhibitoren einsetzbar sind |
US6756392B2 (en) | 2002-02-11 | 2004-06-29 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
EP1567136A1 (fr) * | 2002-11-27 | 2005-08-31 | ALTANA Pharma AG | Inhibiteurs de pde4 et pde3/4 que l'on utilise dans le traitement de la cachexie |
DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
WO2004087150A1 (fr) * | 2003-03-31 | 2004-10-14 | Kyowa Hakko Kogyo Co. Ltd. | Composition pour medicaments |
JPWO2004087151A1 (ja) * | 2003-03-31 | 2006-06-29 | 協和醗酵工業株式会社 | 医薬組成物 |
CA2520577A1 (fr) * | 2003-03-31 | 2004-10-14 | Kyowa Hakko Kogyo Co., Ltd. | Composition pharmaceutique |
JP2006522594A (ja) * | 2003-04-10 | 2006-10-05 | デコデ ジェネティックス イーエイチエフ. | アテローム性動脈硬化症に対する薬剤のスクリーニングにおけるpde4dの使用方法 |
WO2004104022A2 (fr) * | 2003-05-16 | 2004-12-02 | The General Hospital Corporation | Compositions contenant un facteur chimio-tactique epithelial pathogene (eicosanoide et hepoxiline a3), leurs inhibiteurs et leurs procedes d'utilisation |
US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
GB0317484D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
GB0317471D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Novel compounds |
GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
GB0317516D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
CA2594785A1 (fr) * | 2005-01-21 | 2006-07-27 | Pfizer Limited | Formes cristallines cis-5-fluoro-n-[4-(2-hydroxy-4-methylbenzamido) cyclohexyl]-2-(tetrahydrothiopyran-a-yloxy) nicotinamide |
EP1683795A1 (fr) * | 2005-01-21 | 2006-07-26 | Pfizer Limited | Formes crystallines de cis-5-fluoro-N-¬4-(2-hydroxy-4-methylbenzamido)cyclohexyl|-2-(tetrahydrothiopyran-4-yloxy)nicotinamide |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
GB0624282D0 (en) * | 2006-12-05 | 2007-01-10 | Cavalla David | Treatment of cachexia |
WO2008079328A2 (fr) * | 2006-12-22 | 2008-07-03 | Creighton University | Acides gras oméga-5 utiles dans l'inhibition de la 5-lipoxygénase et dans le traitement du cancer |
JP2010523695A (ja) * | 2007-04-11 | 2010-07-15 | アルコン リサーチ, リミテッド | アレルギー性鼻炎およびアレルギー性結膜炎を処置するためのTNFαのインヒビターおよび抗ヒスタミン薬の使用 |
EP2196465A1 (fr) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | Dérivés de (3-oxo)pyridazin-4-ylurée comme inhibiteurs de PDE4 |
EP2226323A1 (fr) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | Nouveaux dérivés de tétrahydropyrazolo [3,4-c]isoquinoléine-5-amine |
USRE46608E1 (en) | 2009-09-01 | 2017-11-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid niacin conjugates and their uses |
DK2473045T3 (en) | 2009-09-01 | 2016-12-12 | Catabasis Pharmaceuticals Inc | Niacin-FATTY ACID CONJUGATES AND THEIR USES |
EP2380890A1 (fr) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | Nouveaux dérivés de 7,8-dihydro-1,6-naphthyridin-5(6h)-one comme PDE4 inhibiteurs |
EP2386555A1 (fr) * | 2010-05-13 | 2011-11-16 | Almirall, S.A. | Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3 |
EP2394998A1 (fr) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | Dérivés de 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl en tant qu'inhibiteurs de la PDE4 |
TWI663977B (zh) * | 2015-03-17 | 2019-07-01 | 理筱龍 | 人蔘皂苷m1用於預防或治療矽肺病之用途 |
US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4861891A (en) * | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
TW429148B (en) | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
JP2000510481A (ja) | 1997-04-04 | 2000-08-15 | ファイザー・プロダクツ・インク | ニコチンアミド誘導体 |
-
2001
- 2001-01-30 EE EEP200200425A patent/EE200200425A/xx unknown
- 2001-01-30 WO PCT/IB2001/000124 patent/WO2001057036A1/fr active IP Right Grant
- 2001-01-30 HU HU0204262A patent/HUP0204262A2/hu unknown
- 2001-01-30 AU AU27002/01A patent/AU2700201A/en not_active Abandoned
- 2001-01-30 CZ CZ20022410A patent/CZ20022410A3/cs unknown
- 2001-01-30 GE GE4906A patent/GEP20043302B/en unknown
- 2001-01-30 EP EP01901333A patent/EP1252158B1/fr not_active Expired - Lifetime
- 2001-01-30 JP JP2001557868A patent/JP3917863B2/ja not_active Expired - Fee Related
- 2001-01-30 IL IL15064101A patent/IL150641A0/xx unknown
- 2001-01-30 AT AT01901333T patent/ATE293624T1/de not_active IP Right Cessation
- 2001-01-30 EA EA200200662A patent/EA004885B1/ru not_active IP Right Cessation
- 2001-01-30 PL PL01357995A patent/PL357995A1/xx not_active Application Discontinuation
- 2001-01-30 OA OA1200200229A patent/OA12169A/en unknown
- 2001-01-30 NZ NZ519547A patent/NZ519547A/en unknown
- 2001-01-30 AP APAP/P/2002/002589A patent/AP2002002589A0/en unknown
- 2001-01-30 BR BR0107964-6A patent/BR0107964A/pt not_active Application Discontinuation
- 2001-01-30 TR TR2002/01880T patent/TR200201880T2/xx unknown
- 2001-01-30 SK SK1014-2002A patent/SK10142002A3/sk unknown
- 2001-01-30 ES ES01901333T patent/ES2238415T3/es not_active Expired - Lifetime
- 2001-01-30 DE DE60110205T patent/DE60110205T2/de not_active Expired - Lifetime
- 2001-01-30 PT PT01901333T patent/PT1252158E/pt unknown
- 2001-01-30 US US10/181,416 patent/US7354941B2/en not_active Expired - Fee Related
- 2001-01-30 MX MXPA02007419A patent/MXPA02007419A/es active IP Right Grant
- 2001-01-30 KR KR1020027009829A patent/KR20020072299A/ko not_active Application Discontinuation
- 2001-01-30 CA CA002398182A patent/CA2398182C/fr not_active Expired - Fee Related
- 2001-01-30 CN CN01804340A patent/CN1404481A/zh active Pending
- 2001-01-31 PE PE2001000110A patent/PE20011058A1/es not_active Application Discontinuation
- 2001-01-31 PA PA20018511201A patent/PA8511201A1/es unknown
- 2001-01-31 SV SV2001000299A patent/SV2002000299A/es not_active Application Discontinuation
- 2001-01-31 AR ARP010100436A patent/AR027337A1/es not_active Application Discontinuation
- 2001-01-31 CO CO01007017A patent/CO5261634A1/es not_active Application Discontinuation
- 2001-01-31 UY UY26569A patent/UY26569A1/es not_active Application Discontinuation
- 2001-01-31 TN TNTNSN01020A patent/TNSN01020A1/fr unknown
- 2001-01-31 GT GT200100022A patent/GT200100022A/es unknown
- 2001-06-30 HN HN2001000019A patent/HN2001000019A/es unknown
-
2002
- 2002-06-13 IS IS6421A patent/IS6421A/is unknown
- 2002-06-20 BG BG106852A patent/BG106852A/bg unknown
- 2002-07-23 MA MA26739A patent/MA26870A1/fr unknown
- 2002-07-29 ZA ZA200206033A patent/ZA200206033B/en unknown
- 2002-07-30 NO NO20023613A patent/NO20023613L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EE200200425A (et) | Selektiivsete PDE4 isosüümide inhibiitoritena kasulikud nikotiinamiidi bensokondenseerunud heterotsüklüülderivaadid | |
EE200300360A (et) | PDE4 isosüümide inhibiitoritena kasutatavad nikotiinamiidi biarüülderivaadid | |
EE200200426A (et) | PDE4 isosüümide inhibiitoritena kasulikud pürimidiinkarboksamiidid | |
DE60317466D1 (de) | Nicotinamid-derivate als pde4-hemmer | |
EE200300361A (et) | PDE4 isosüümide inhibiitoritena kasutatavad eetriderivaadid | |
ATE323072T1 (de) | Pyrimidin-derivate als selective inhibitoren von cox-2 | |
IS8242A (is) | Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar | |
PT1296981E (pt) | Derivados substituidos da pirrolopiridinona uteis como inibidores da fosfodiesterase | |
NO20026010L (no) | Substituerte quinazolinderivater og deres anvendelse som inhibitorer | |
MA25836A1 (fr) | Derives de pyridine avec une activite inhibitrice de ikb-kinase (ikk-b) | |
GB0203193D0 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
NO20021959D0 (no) | Tetrahydrotiopyranftalazinon-derivater som PDE4-inhibitorer | |
NO20035206D0 (no) | Pyrimidin-derivater anvendelige som selektive COX-2- inhibitorer | |
GB0317472D0 (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
SI1252158T1 (en) | Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes | |
IS7366A (is) | Nikótínamíð afleiður nytsamlegar sem PDE4 hindrar | |
GT200300035A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 | |
DK1252158T3 (da) | Benzo-annelleret heterocyclyl-nicotinamed-derivater, der er nyttige som selektive inhibitorer af PDE4-isozymer | |
GB0220999D0 (en) | Nicotinamide derivatives useful as pde4 inhibitors | |
GB0224453D0 (en) | Nicotinamide derivatives useful as PDE4 inhibitors | |
DOP2003000586A (es) | Derivados de nicotinamida utiles como inhibidores de pde4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HB1A | Correction of owner name or address |